再鼎醫藥(09688.HK):治療晚期胃腸道間質瘤新藥獲內地批准上市
再鼎醫藥(09688.HK)公布,國家藥監局已批准擎樂(瑞派替尼)的新藥上市申請,該藥物為由Deciphera(DCPH.US)開發的一種開關調控酪氨酸激(酉每)抑制劑,用於治療既往接受過包括伊馬替尼在內的三種或以上激(酉每)抑制劑治療的晚期胃腸道間質瘤成人患者。
公司與Deciphera於2019年6月訂立獨家授權協議,公司取得Deciphera若干專利及專有技術的獨家授權,於大中華地區開發及商業化包括擎樂在內的產品,用於防治、預防、治療、治愈或緩解任何人類疾病或病症的領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.